Act-Hib 30 mcg (Tetanus Protein KIT) 30 MCG

ACT-HIB 30 MCG is a vaccine kit designed to protect against Haemophilus influenzae type b (Hib) infections. This intramuscular injection is manufactured by Sanofi Pasteur Limited in Canada.

Strength

30 MCG

Pack Size

5X1VIAL - 5X0.5ML AMP

Manufacturer / TM Owner

SANOFI PASTEUR LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ACT-HIB 30 MCG is used to prevent invasive diseases caused by Haemophilus influenzae type b (Hib), such as meningitis and sepsis. It is typically administered to infants and children as part of their routine immunization schedule. The vaccine works by stimulating the body's immune response to develop protection against Hib bacteria.

Side Effects

Common effects of ACT-HIB 30 MCG may include mild redness, swelling, or tenderness at the injection site. Some individuals might experience a low-grade fever, irritability, or loss of appetite. These effects are usually mild and temporary.

Precautions & Warnings

ACT-HIB 30 MCG should be administered by a healthcare professional. It is important to inform the healthcare provider about any allergies, particularly to yeast or any component of the vaccine. Individuals with a history of severe allergic reactions to a previous dose of ACT-HIB or any of its components should avoid this vaccine.

Avoid Interactions

ACT-HIB 30 MCG may interact with other vaccines or medications. It is generally safe to administer simultaneously with other vaccines, but specific guidelines should be followed. Always consult a healthcare provider before combining ACT-HIB with other treatments.

Frequently Asked Questions

ACT-HIB 30 MCG is used to prevent invasive diseases caused by Haemophilus influenzae type b (Hib), such as meningitis and sepsis.

ACT-HIB 30 MCG is administered intramuscularly, typically in the thigh or upper arm, by a healthcare professional.

Common side effects may include mild redness, swelling, or tenderness at the injection site, as well as a low-grade fever or irritability.

ACT-HIB 30 MCG can often be given with other vaccines, but specific guidelines should be followed. Consult a healthcare provider for personalized advice.

Individuals with a history of severe allergic reactions to a previous dose of ACT-HIB or any of its components should avoid this vaccine.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.